title: Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients.
abstract: Clinical data indicate that prognostic stratification of radically resected colorectal cancer based on disease stage only may not be always be adequate. Preclinical findings suggest that cancer stem cells may influence the biological behaviour of colorectal cancer independently from stage: objective of the study was to assess whether a panel of stemness markers were correlated with clinical outcome in resected stage II and III colon cancer patients. A panel of 66 markers of stemness were analysed and thus patients were divided into two groups (A and B) with most patients clustering in a manner consistent with different time to relapse by using a statistical algorithm. A total of 62 patients were analysed. Thirty-six (58%) relapsed during the follow-up period (range 1.63-86.5 months). Twelve (19%) and 50 (81%) patients were allocated into group A and B, respectively. A significantly different median relapse-free survival was observed between the 2 groups (22.18 vs 42.85 months, p=0.0296). Among of all genes tested, those with the higher "weight" in determining different prognosis were CD44, ALCAM, DTX2, HSPA9, CCNA2, PDX1, MYST1, COL1A1 and ABCG2. This analysis supports the idea that, other than stage, biological variables, such as expression levels of colon cancer stem cell genes, may be relevant in determining an increased risk of relapse in resected colorectal cancer patients.
authors.affiliation: Department of Medical Oncology, AO Ospedali Riuniti-UNIVPM, Ancona, Italy.
authors.forename: Riccardo
authors.initials: R
authors.lastname: Giampieri
authors.forename: Mario
authors.initials: M
authors.lastname: Scartozzi
authors.forename: Cristian
authors.initials: C
authors.lastname: Loretelli
authors.forename: Francesco
authors.initials: F
authors.lastname: Piva
authors.forename: Alessandra
authors.initials: A
authors.lastname: Mandolesi
authors.forename: Giovanni
authors.initials: G
authors.lastname: Lezoche
authors.forename: Michela
authors.initials: M
authors.lastname: Del Prete
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bittoni
authors.forename: Luca
authors.initials: L
authors.lastname: Faloppi
authors.forename: Maristella
authors.initials: M
authors.lastname: Bianconi
authors.forename: Luca
authors.initials: L
authors.lastname: Cecchini
authors.forename: Mario
authors.initials: M
authors.lastname: Guerrieri
authors.forename: Italo
authors.initials: I
authors.lastname: Bearzi
authors.forename: Stefano
authors.initials: S
authors.lastname: Cascinu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D003110:Colonic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D009367:Neoplasm Staging; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor
references.citation: Clin Exp Metastasis. 2010 Oct;27(7):517-27
references.pmid: 20617370
references.citation: Cell Transplant. 2010;19(6):865-77
references.pmid: 20587145
references.citation: Clin Cancer Res. 2011 Nov 1;17(21):6934-43
references.pmid: 21918173
references.citation: N Engl J Med. 2004 Jun 3;350(23):2343-51
references.pmid: 15175436
references.citation: Cancer Lett. 2013 Jan 28;328(2):226-34
references.pmid: 23017941
references.citation: J Clin Invest. 2008 Jun;118(6):2111-20
references.pmid: 18497886
references.citation: J Biol Chem. 2009 Jan 9;284(2):1177-89
references.pmid: 19004834
references.citation: J Clin Oncol. 2011 Apr 10;29(11):1465-71
references.pmid: 21383294
references.citation: J Gastrointest Surg. 2012 Mar;16(3):646-55
references.pmid: 22194062
references.citation: FASEB J. 2012 Jun;26(6):2648-56
references.pmid: 22415308
references.citation: Surg Oncol. 2012 Jun;21(2):103-7
references.pmid: 21764578
references.citation: Biochem Biophys Res Commun. 2001 Jul 27;285(4):939-44
references.pmid: 11467842
references.citation: Eur J Cancer. 2010 Feb;46(3):642-9
references.pmid: 20005089
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8671-8
references.pmid: 16314627
references.citation: J Cancer. 2012;3:231-40
references.pmid: 22670157
references.citation: Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45
references.pmid: 12511867
references.citation: J Cancer Res Clin Oncol. 2013 Feb;139(2):211-22
references.pmid: 23052691
references.citation: Am J Physiol Gastrointest Liver Physiol. 2011 Aug;301(2):G347-55
references.pmid: 21596996
references.citation: Acta Pharmacol Sin. 2013 Jun;34(6):793-804
references.pmid: 23736004
references.citation: J Pathol. 2009 Dec;219(4):427-34
references.pmid: 19621338
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3732-8
references.pmid: 17704423
references.citation: J Mol Signal. 2012 Aug 06;7(1):11
references.pmid: 22866952
references.citation: Oncol Lett. 2012 Jul;4(1):75-79
references.pmid: 22807964
references.citation: BMC Bioinformatics. 2012 Jun 25;13 Suppl 10:S7
references.pmid: 22759431
references.citation: J Exp Clin Cancer Res. 2012 Sep 11;31:71
references.pmid: 22964035
references.citation: Oncol Rep. 2012 Oct;28(4):1301-8
references.pmid: 22895640
references.citation: Front Biosci (Landmark Ed). 2011 Jan 01;16:1651-62
references.pmid: 21196254